The role of cell-mediated immunity in the resistance of young adult mice to subcutaneous herpes simplex virus (HSV) type I infection was studied in mice receiving immunosuppressive doses of antilymphocyte sera (ALS) or antithymocyte sera (ATS). The effectiveness of these treatments to reduce cellmediated responses was measured by their ability to prolong the life of allografts transplanted to ALS-or ATS-treated mice. It was found that subcutaneous infection of these mice with HSV resulted in spread of virus from the site of' inoculation to the central nervous system. Neutralizing antibody could not be detected in the sera of ALS-or ATS-treated mice after HSV inoculation. Mice. Five-week-old SJL mice (Jackson Laboratory, Bar Harbor, Maine) or 4-to 6-week-old C57 black mice (Cumberland View Farms, Clinton, Tenn.) were used in all experiments. Mice to be immunosuppressed with irradiation were placed in groups of 18 in a circular lucite box on a revolving turntable 50 cm from the target of a 250-kV-power X-ray source (Maxitron 700, General Electric) operated at 20-mA tube current with a 1.13-mm Cu filter. The exposure dose rate delivered was 110 R per min as measured by a Victoreen R-meter (model 570 condenser R-meter, Victoreen Instrument Division, Victoreen, Inc., Cleveland, Ohio).
The role of cell-mediated immunity in the resistance of young adult mice to subcutaneous herpes simplex virus (HSV) type I infection was studied in mice receiving immunosuppressive doses of antilymphocyte sera (ALS) or antithymocyte sera (ATS). The effectiveness of these treatments to reduce cellmediated responses was measured by their ability to prolong the life of allografts transplanted to ALS-or ATS-treated mice. It was found that subcutaneous infection of these mice with HSV resulted in spread of virus from the site of' inoculation to the central nervous system. Neutralizing antibody could not be detected in the sera of ALS-or ATS-treated mice after HSV inoculation. Passive transf'er of neutralizing antibody to ATS-treated mice did not restore resistance to subcutaneous HSV infection. However, adoptive transfer of' HSV-sensitized spleen cells did provide significant protection against infection unless the spleen cells were treated with ATS prior to transfer. These experiments suggest that lymphocytes are involved in a cell-mediated response to subcutaneous HSV infection and demonstrate the importance of a noncompromised immune response in controlling spread of HSV from localized areas of infection.
Persistence in its natural host for long periods is a unique property of herpes simplex virus (HSV) pathogenesis. This persistence is often manifested as recurrent inflammatory lesions on cutaneous surfaces of individuals who have recovered from a primary infection. Since these infections can continually reappear in the presence of humoral (3, 4) and cell-mediated reactions against HSV (24) , immunological mechanisms do not appear to play an important role in controlling activation of virus within the host. However, it has been observed that patients undergoing immunosuppressive therapy often suffer more severe attacks of recurrent herpetic infections which extend over larger areas of their body (25) . Thus, the host's defense mechanisms may be a more decisive factor in limiting dissemination of virus from localized lesions than in preventing recurrent infections.
Experimental subcutaneous HSV infections in mice have also shown that a host can contain virus within localized areas unless the immune response has been compromised with immunosuppressive agents (20 Mice. Five-week-old SJL mice (Jackson Laboratory, Bar Harbor, Maine) or 4-to 6-week-old C57 black mice (Cumberland View Farms, Clinton, Tenn.) were used in all experiments. Mice to be immunosuppressed with irradiation were placed in groups of 18 in a circular lucite box on a revolving turntable 50 cm from the target of a 250-kV-power X-ray source (Maxitron 700, General Electric) operated at 20-mA tube current with a 1.13-mm Cu filter. The exposure dose rate delivered was 110 R per min as measured by a Victoreen R-meter (model 570 condenser R-meter, Victoreen Instrument Division, Victoreen, Inc., Cleveland, Ohio).
Assay of antilymphoid sera. Rabbit anti-mouse lymphocyte sera (ALS) or antithymocyte sera (ATS) and normal rabbit sera (NRS) were (1 x 105 PFU/ml) was placed on the abrased area and rubbed in with the shank of the needle. This method of immunization resulted in an acute inflammatory infection at the site of inoculation. Control mice were treated with HBSS in place of virus. Nine to twelve days later, spleens were removed from the mice and extruded aseptically from their capsules. After being minced with scissors, the material was filtered through sterile cotton gauze to remove clumps of tissue. Cells were washed and resuspended in HBSS to 108 cells/ml. Adherent cells were depleted by placing 25 ml of the suspension in glass 32-ounce (ca. 0.95 liter) prescription bottles at 37 C in 5% CO2 for 90 min. Nonadherent cells were decanted after gentle rotation of the flask. The cells were washed and resuspended in HBSS. Differential counts of spleen cell preparations showed approximately 95% lymphocytes, 4% monocytes, and 1% segmented cells. Several samples of donor spleen cells were also frozen and thawed twice and were found not to contain HSV as determined by isolation attempts on Vero cells. In some experiments bone marrow cells were transferred in addition to spleen cells. These were harvested from both femurs of SJL mice by aspiration with HBSS from a 27-gauge needle (30) . The number of viable cells was determined by hemocytometer counts using the trypan blue exclusion test. Recipient mice received viable cells intravenously.
Sindbis virus-sensitized spleen cells were harvested 9 to 12 days after mice were inoculated subcutaneously in rear footpads with 5 x 106 PFU of Sindbis virus. The cells were prepared as above for transfer to recipient mice. 
RESULTS
Effect of ATS or ALS on allograft survival. Five-week-old SJL mice were given five intraperitoneal injections of 0.4 ml of ALS or ATS on alternate days. Normal rabbit serum was given as a control. After the second injection, skin from C57 mice was transplanted onto treated SJL mice. The mean survival time of these skin grafts is shown in Table 1 . The routine of ATS or ALS treatment increased the mean survival time over NRS-treated mice by approximately 10 days. This was highly significant as determined by the Student t test (P < 0.01).
Effect of ALS or ATS on subcutaneous HSV infection. Employing the same preparations and administration schedule, groups of 10 mice each were treated with ALS, ATS, or NRS and inoculated subcutaneously with HSV in one rear footpad after the second treatment. As shown in Table 2 , less than 10% of the mice in the NRS-treated group died from infection, whereas 80% or more of the ALS-or ATS-treated VOL. 12, 1975 on October 25, 2017 by guest http://iai.asm.org/ Downloaded from Effect of ALS or ATS on neutralizing antibody. Three groups of 15 mice each were given a standard routine of ATS, ALS, or NRS treatment. A fourth group was untreated. After viral inoculation, three mice were randomly selected on alternate days from each group and bled from the retroorbital plexus. Their sera were pooled and assayed for neutralizing antibody. The amount of neutralizing antibody detected is illustrated in Fig. 1 . Circulating antibody was present by day 7 postinfection in NRS-treated or untreated mice, but could not be detected in ALS-or ATS-treated mice. Thus, both ALS and ATS were effective in reducing the ability of the host to produce neutralizing antibody in response to a subcutaneous HSV infection.
Passive transfer of antibody. The importance of circulating antibody in controlling subcutaneous HSV infections could not be evaluated with antilymphoid sera since suppression of an antibody response to HSV accompanied both ATS or ALS treatment. Therefore, the influence of antibody on the course of subcutaneous HSV infection was directly determined by passively transferring sera from rabbits hyperimmunized to HSV to ATS-treated mice before HSV infection. Twenty mice received two 0.4-ml doses of ATS on alternate days. After the second ATS treatment, 10 of the mice received an intravenous injection of 0.4 ml of rabbit anti-HSV hyperimmune serum (HSV neutralizing titer = 1/640). Six hours later, all mice were inoculated subcutaneously in the rear footpad with 1 x 106 PFU of HSV. This was followed by three additional ATS treatments on days 2, 4, and 6 postinfection. Passive antibody did not significantly alter the outcome of HSV infection (P < 0.01, chi square test) (Fig. 2) . The levels of passive antibody remaining in circulation during the 10-day experiment were determined by passively transferring an equal amount of neutralizing antibody to a group of 12 mice treated with identical doses of ATS. Two mice were removed from this group on alternate days and bled from the retroorbital plexus. Their sera were pooled and assayed for antibody. Neutralizing antibody remained in the circulatory system throughout the period required for HSV to spread from the footpad to the central nervous system (Fig. 3) . The data also show that passive antibody transferred was comparable to the levels of antibody physiologically produced in untreated mice after subcutaneous inoculation. These results suggest that circulating antibody produced by the host in response to a subcutaneous HSV infection is not an important defense mechanism in preventing spread of virus to the central nervous system under these conditions.
Transfer of sensitized spleen cells to HSVinfected mice. The previous experiments demonstrated that passive antibody cannot restore resistence of young adult mice to HSV infection after treatment with antilymphoid sera. This suggests that a cellular response is of greater importance than an antibody response in recovery of the host after infection. To further investigate the influence of a cell-mediated response on the course of infection, HSV-sensitized spleen cells were transferred to mice before virus inoculation. Mice were immunosuppressed with 450 R of X irradiation prior to cell transfer to increase their susceptibility to HSV infection (20) . Six hours later, groups of mice received intravenously normal spleen cells or HSV-sensitized spleen cells. Bone marrow cells were given to one-half of each group in addition to spleen cells to replace any monocyte precur- sor cells which may have been damaged by the X irradiation dose (31) . The bone marrow provided a potential population of monocytes which have been shown to be required in many cell-mediated responses (13, 14) . Spleen cells from Sindbis virus-inoculated mice were also transferred to irradiated mice to serve as an additional control. The spleens were harvested from these mice at the time a maximum immune response to Sindbis virus has been re- (Fig. 4) .
Immune spleen cells were also treated with ATS prior to their transfer into irradiated recipients to deplete the lymphocyte population. ATS treatment of spleen cells capable of protecting mice against HSV infection eliminated the potential of these cells to protect susceptible mice against subcutaneous inoculation (Table 5) .
DISCUSSION
Resistance and recovery of young adult mice to HSV infection was initially associated with the host's macrophages (10, 11) . These cells were shown to play an important role in preventing spread of virus within infected tissues by inhibiting the multiplication of ingested virus (29) . However, it soon became apparent (18) .
In this investigation, antilymphoid sera was initially used to determine the contributions of lymphocytes in controlling subcutaneous HSV infection. Mackaness has shown that a population of specifically sensitized lymphocytes is required to trigger a cell-mediated response to an infection (16) . Antilymphoid sera will selectively deplete this population of antigen-reactive recirculating lymphocytes, thereby limiting the potential of the host to mediate a cellular response (12) . In the present study, both ATS and ALS were used to treat infected mice since there has been some claim of the superiority of one type of serum over the other (32 (2) . Mononuclear cells have also been observed to interact with antibody, augmenting their ability to kill virus-infected cells (27) . These mechanisms could be operating in local tissues to influence the outcome of infection even though controlling the susceptibility of mice to the virus. Also, the HSV-neutralizing sera used for passive transfer experiments reported here may not contain the necessary cytophilic antibodies involved in these important reactions.
Direct evidence for participation of immunologically competent cells in recovery of mice from subcutaneous infection was obtained by adoptive transfer of HSV-immune cells to irradiated recipients. These cells were highly effective in protecting irradiated mice against a subcutaneous virus challenge when harvested from spleens of mice recovering from a subcutaneous HSV infection. The reaction was specific since protection could not be adoptively transferred with cells harvested from mice immunized to heterogenous Sindbis virus. The ability of ATS treatment to reduce the potential of immune spleen cells to transfer immunity into recipients identified the reactive cells as a species of lymphocyte. These findings indicate that sensitized lymphocytes are an important barrier in limiting spread of virus from initial sites of infection in this system and support the conclusions that cell-mediated immunity is involved in recovery of mice from subcutaneous HSV infection. The precise mechanism by which sensitized cells protect recipient mice against a subcutaneous HSV infection is not understood. However, the results of several in vitro studies suggest that the host's immune response may be able to react to HSV-infected tissues at the site of inoculation to limit further spread of virus. Many viruses produce specific antigens on the surface of cells they infect. When lymphocyte populations from animals sensitized to a particular virus are then placed with these cells in culture, they respond to the surface antigens and destroy the infected cells (15, 16, 28) . Sensitized mouse spleen cells have also been shown to control spread of HSV in cell culture (5) , but the ability of these cells to protect irradiated recipients in vivo in the absence of bone marrow was not expected. Blood monocytes are required in many cell-mediated responses, where they infiltrate into the site of reaction to become the effector cell (16) . Irradiation severely damages the ability of bone marrow to resupply these cells to the host (31) . It is unlikely that the 108 spleen cells adoptively transferred in these experiments could have provided the necessary numbers of monocytes since in other systems the spleen has been shown not to be the source of monocytes dur-i ing a cell-mediated reaction (7, 19 infection. The ability of antilymphoid sera to both decrease host resistance to infection and eliminate adoptive transfer of immunity supports the concept that lymphocytes are the cells which initiate the cell-mediated response leading to recovery of the host in this disease.
